Benjamin J Cowling1, Shuo Feng1, Lyn Finelli2, Andrea Steffens2, Ashley Fowlkes3. 1. WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region. 2. Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA, United States. 3. Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA, United States. Electronic address: AFowlkes@cdc.gov.
Abstract
BACKGROUND: Influenza vaccines are now widely used to reduce the burden of annual epidemics of influenza virus infections. Influenza vaccine effectiveness (VE) is monitored annually to determine VE against each season's circulating influenza strains in different groups such as children, adults and the elderly. Few prospective surveillance programs are available to evaluate influenza VE against medically attended illness for patients of all ages in the United States. METHODS: We conducted surveillance of patients with acute respiratory illnesses in 101 clinics across the US during three consecutive influenza seasons. We analyzed laboratory testing results for influenza virus, self-reported vaccine history, and patient characteristics, defining cases as patients who tested positive for influenza virus and controls as patients who tested negative for influenza virus. Comparison of influenza vaccination coverage among cases versus controls, adjusted for potential confounders, was used to estimate VE as one minus the adjusted odds ratio multiplied by 100%. RESULTS: We included 10,650 patients during three influenza seasons from August 2010 through December 2013, and estimated influenza VE in children 6m-5y of age (58%; 95% CI: 49%-66%), children 6-17y (45%; 95% CI: 34%-53%), adults 18-49y (36%; 95% CI: 24%, 46%), and adults ≥50y (34%, 95% CI: 13%, 51%). VE was higher against influenza A(H1N1) compared to A(H3N2) and B. CONCLUSIONS: Our estimates of moderate influenza VE confirm the important role of vaccination in protecting against medically attended influenza virus infection. Published by Elsevier Ltd.
BACKGROUND:Influenza vaccines are now widely used to reduce the burden of annual epidemics of influenza virus infections. Influenza vaccine effectiveness (VE) is monitored annually to determine VE against each season's circulating influenza strains in different groups such as children, adults and the elderly. Few prospective surveillance programs are available to evaluate influenza VE against medically attended illness for patients of all ages in the United States. METHODS: We conducted surveillance of patients with acute respiratory illnesses in 101 clinics across the US during three consecutive influenza seasons. We analyzed laboratory testing results for influenza virus, self-reported vaccine history, and patient characteristics, defining cases as patients who tested positive for influenza virus and controls as patients who tested negative for influenza virus. Comparison of influenza vaccination coverage among cases versus controls, adjusted for potential confounders, was used to estimate VE as one minus the adjusted odds ratio multiplied by 100%. RESULTS: We included 10,650 patients during three influenza seasons from August 2010 through December 2013, and estimated influenza VE in children 6m-5y of age (58%; 95% CI: 49%-66%), children 6-17y (45%; 95% CI: 34%-53%), adults 18-49y (36%; 95% CI: 24%, 46%), and adults ≥50y (34%, 95% CI: 13%, 51%). VE was higher against influenza A(H1N1) compared to A(H3N2) and B. CONCLUSIONS: Our estimates of moderate influenza VE confirm the important role of vaccination in protecting against medically attended influenza virus infection. Published by Elsevier Ltd.
Authors: Danuta M Skowronski; Catharine Chambers; Suzana Sabaiduc; Gaston De Serres; Anne-Luise Winter; James A Dickinson; Jonathan Gubbay; Kevin Fonseca; Hugues Charest; Mel Krajden; Martin Petric; Salaheddin M Mahmud; Paul Van Caeseele; Nathalie Bastien; Alireza Eshaghi; Yan Li Journal: J Infect Dis Date: 2015-03-17 Impact factor: 5.226
Authors: Ashley Fowlkes; Andrea Steffens; Jon Temte; Steve Di Lonardo; Lisa McHugh; Karen Martin; Heather Rubino; Michelle Feist; Carol Davis; Christine Selzer; Jose Lojo; Oluwakemi Oni; Katie Kurkjian; Ann Thomas; Rachelle Boulton; Nicole Bryan; Ruth Lynfield; Matthew Biggerstaff; Lyn Finelli Journal: Lancet Respir Med Date: 2015-08-21 Impact factor: 30.700
Authors: Avram Levy; Sheena G Sullivan; Simone S Tempone; Kerry L M Wong; Annette K Regan; Gary K Dowse; Paul V Effler; David W Smith Journal: Vaccine Date: 2014-09-16 Impact factor: 3.641
Authors: Huong Q McLean; Mark G Thompson; Maria E Sundaram; Jennifer K Meece; David L McClure; Thomas C Friedrich; Edward A Belongia Journal: Clin Infect Dis Date: 2014-09-29 Impact factor: 9.079
Authors: Melissa K Andrew; Susan K Bowles; Graham Pawelec; Laura Haynes; George A Kuchel; Shelly A McNeil; Janet E McElhaney Journal: Drugs Aging Date: 2019-01 Impact factor: 3.923
Authors: Nazila M Dabestani; Andrew J Leidner; Eric E Seiber; Hyoshin Kim; Samuel B Graitcer; Ivo M Foppa; Carolyn B Bridges Journal: Prev Med Date: 2019-05-29 Impact factor: 4.018
Authors: Huiying Chua; Shuo Feng; Joseph A Lewnard; Sheena G Sullivan; Christopher C Blyth; Marc Lipsitch; Benjamin J Cowling Journal: Epidemiology Date: 2020-01 Impact factor: 4.822
Authors: Matthew P Cheng; Michael G Kozoriz; Amir A Ahmadi; John Kelsall; Katryn Paquette; Jake M Onrot Journal: Allergy Asthma Clin Immunol Date: 2016-02-11 Impact factor: 3.406
Authors: Melissa K Andrew; Vivek Shinde; Todd Hatchette; Ardith Ambrose; Guy Boivin; William Bowie; Ayman Chit; Gael Dos Santos; May ElSherif; Karen Green; François Haguinet; Scott A Halperin; Barbara Ibarguchi; Jennie Johnstone; Kevin Katz; Joanne M Langley; Jason LeBlanc; Mark Loeb; Donna MacKinnon-Cameron; Anne McCarthy; Janet McElhaney; Allison McGeer; Michaela K Nichols; Jeff Powis; David Richardson; Makeda Semret; Grant Stiver; Sylvie Trottier; Louis Valiquette; Duncan Webster; Lingyun Ye; Shelly A McNeil Journal: BMC Infect Dis Date: 2017-12-29 Impact factor: 3.090
Authors: Mazhar Hussain; Henry D Galvin; Tatt Y Haw; Ashley N Nutsford; Matloob Husain Journal: Infect Drug Resist Date: 2017-04-20 Impact factor: 4.003
Authors: Danuta M Skowronski; Catharine Chambers; Suzana Sabaiduc; Gaston De Serres; Anne-Luise Winter; James A Dickinson; Mel Krajden; Jonathan B Gubbay; Steven J Drews; Christine Martineau; Alireza Eshaghi; Trijntje L Kwindt; Nathalie Bastien; Yan Li Journal: Clin Infect Dis Date: 2016-03-29 Impact factor: 9.079